Hostname: page-component-74656f9884-8r8nv Total loading time: 0 Render date: 2026-11-10T09:43:33.296Z Has data issue: false hasContentIssue false
  • English
  • Français

Basic science (May–June 2005)

Published online by Cambridge University Press:  15 November 2005

R. Sutherland  and
J. Scorer
R. Sutherland
Affiliation:
Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
J. Scorer
Affiliation:
Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Information

Type
Journals Watch
Information
Breast Cancer Online , Volume 8 , Issue 10 , October 2005 , e54
Copyright
2005 Cambridge University Press

Articles in this list have been selected from material published since April 2005. They represent recommended reading only.

When available the citations are linked to the abstract held on PubMed (Medline) and CrossRef.

References

Ahnstrom M, Nordenskjold B, Rutqvist LE, Skoog L, Stal O. Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance. Breast Cancer Res Tr 2005; 91: 145–151.Google Scholar
Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 2005; 26: 331–345.Google Scholar
Buluwela L, Pike J, Mazhar D, Kamalati T, Hart SM, Al-Jehani R, Yahaya H, Patel N, Sarwarl N, Heathcote DA, Schwickerath O, Phoenix F, Hill R, Aboagye E, Shousha S, Waxman J, Lemoine NR, Zelent A, Coombes RC, Ali S. Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF. Gene Ther 2005; 12: 862.Google Scholar
Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, Camuso AE, Gottardis M, Greer AF, Ho CP, Hurlburt W, Li AX, Saulnier M, Velaparthi U, Wang C, Wen ML, Westhouse RA, Wittman M, Zimmermann K, Rupnow BA, Wong TW. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 2005; 65: 3781–3787.Google Scholar
Chappuis PO, Donato E, Goffin JR, Wong N, Begin LR, Kapusta LR, Brunet JS, Porter P, Foulkes WD. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol 2005; 16: 735–742.Google Scholar
Choudhuri T, Pal S, Das T, Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G(2) phase of cell cycle in a p53-dependent manner. J Biol Chem 2005; 280: 20059–20068.Google Scholar
Cicek M, Fukuyama R, Welch DR, Sizemore N, Casey G. Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappa B activity. Cancer Res 2005; 65: 3586–3595.Google Scholar
Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, Thoresen SO, Foulkes WD, Akslen LA. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidem Biomar Prev 2005; 14: 1108–1112.Google Scholar
Collins LC, Schnitt SJ. HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Modern Pathol 2005; 18: 615–620.Google Scholar
Cui Y, Shu XO, Cai QY, Jin F, Cheng JR, Cai H, Gao YT, Zheng W. Association of breast cancer risk with a common functional polymorphism (Asp327Asn) in the sex hormone-binding globulin gene. Cancer Epidem Biom Prev 2005; 14: 1096–1101.Google Scholar
Cummings SR, Lee JS, Lui LY, Stone K, Ljung BM, Cauleys JAGAOFRG. Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study. Cancer Epidem Biom Prev 2005; 14: 1047–1051.Google Scholar
Dai HY, van’t Veer L, Lamb J, He YD, Mao M, Fine BM, Bernards R, de Vijver MV, Deutsch P, Sachs A, Stoughton R, Friend S. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005; 65: 4059–4066.Google Scholar
Diaz-Cruz ES, Shapiro CL, Brueggemeier RW. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocr Metab 2005; 90: 2563–2570.Google Scholar
Esslimani-Sahla M, Kramar A, Simony-Lafontaine J, Warner M, Gustafsson JA, Rochefort H. Increased estrogen receptor beta cx expression during mammary carcinogenesis. Clin Cancer Res 2005; 11: 3170–3174.Google Scholar
Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 2005; 11: 3315–3319.Google Scholar
Fabre-Lafay S, Garrido-Urbani S, Reymond N, Goncalves A, Dubreuil P, Lopez M. Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. J Biol Chem 2005; 280: 19543–19550.Google Scholar
Gburcik V, Bot N, Maggiolini M, Picard D. SPBP is a phosphoserine-specific repressor of estrogen receptor alpha. Mol Cell Biol 2005; 25: 3421–3430.Google Scholar
Gery S, Tanosaki S, Bose S, Bose N, Vadgama J, Koeffler HP. Down-regulation and growth inhibitory role of C/EBP alpha in breast cancer. Clin Cancer Res 2005; 11: 3184–3190.Google Scholar
Gouaze V, Liu YY, Prickett CS, Yu JY, Giuliano AE, Cabot MC. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res 2005; 65: 3861–3867.Google Scholar
Hannemann J, Oosterkamp HM, Bosch CAJ, Velds A, Wessels LFA, Loo C, Rutgers EJ, Rodenhuis S, van de Vijver MJ. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005; 23: 3331–3342.Google Scholar
Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. J Am Med Assoc 2005; 293: 2479–2486.Google Scholar
Huang XM, Bennett M, Thorpe PE. A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. Cancer Res 2005; 65: 4408–4416.Google Scholar
Ioannidis P, Mahaira LG, Perez SA, Gritzapis AD, Sotiropoulou PA, Kavalakis GJ, Antsaklis AI, Baxevanis CN, Papamichail M. CRD-BP/IMP1 expression characterizes cord blood CD34(+) stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cells. J Biol Chem 2005; 280: 20086–20093.Google Scholar
Jin QR, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R, Henriksson R, Chen BW, Pamula J, Pekala W, Zientek H, Rogozinska-Szczepka J, Utracka-Hutka B, Hallmans G, Forsti A. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 2005; 11: 3647–3653.Google Scholar
Johnson MM, Houck J, Chen C. Screening for deleterious nonsynonymous single-nucleoticle polymorphisms in genes involved in steroid hormone metabolism and response. Cancer Epidem Biom Prev 2005; 14: 1326–1329.Google Scholar
Jones LP, Li ML, Halama ED, Ma YX, Lubet R, Grubbs CJ, Deng CX, Rosen EM, Furth PA. Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer. Oncogene 2005; 24: 3554–3562.Google Scholar
Kavanagh AM, Cawson J, Byrnes GB, Giles GG, Marr G, Tong B, Gertig DM, Hopper JL. Hormone replacement therapy, percent mammographic density, and sensitivity of mammography. Cancer Epidem Biom Prev 2005; 14: 1060–1064.Google Scholar
Kowalska E, Narod SA, Huzarski T, Zajaczek S, Huzarska J, Gorski B, Lubinski J. Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation. Cancer Epidem Biom Prev 2005; 14: 1302–1306.Google Scholar
Kurian AW, Mills MA, Jaffee M, Sigal BM, Chun NM, Kingham KE, Collins LC, Nowels KW, Plevritis SK, Garber JE, Ford JM, Hartman AR. Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. Cancer Epidem Biom Prev 2005; 14: 1082–1089.Google Scholar
Lang JY, Chen H, Zhou J, Zhang YX, Zhang XW, Li MH, Lin LP, Zhang JS, Waalkes MP, Ding J. Antimetastatic effect of salvicine on human breast cancer MDA-MB-435 orthotopic xenograft is closely related to Rho-dependent pathway. Clin Cancer Res 2005; 11: 3455–3464.Google Scholar
Lanzino M, De Amicis F, McPhaul MJ, Marsico S, Panno ML, Ando S. Endogenous coactivator ARA70 interacts with estrogen receptor alpha (ER alpha) and modulates the functional ER alpha/androgen receptor interplay in MCF-7 cells. J Biol Chem 2005; 280: 20421–20430.Google Scholar
Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R. Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res 2005; 65: 3796–3805.Google Scholar
Martens JWM, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-De Vries J, Sieuwerts AM, Portengen H, Gelder MEM, Piepenbrock C, Olek A, Hofler H, Kiechle M, Klijn JGM, Schmitt M, Maier S, Foekens JA. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 2005; 65: 4101–4107.Google Scholar
Mikhitarian K, Gillanders WE, Almeida JS, Martin RH, Varela JC, Metcalf JS, Cole DJ, Mitas M. An innovative microarray strategy identities informative molecular markers for the detection of micrometastatic breast cancer. Clin Cancer Res 2005; 11: 3697–3704.Google Scholar
Mukherjee S, Conrad SE. c-Myc suppresses p21(WAF1/CIP1) expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J Biol Chem 2005; 280: 17617–17625.Google Scholar
Poola I, DeWitty RL, Marshalleck JJ, Bhatnagar R, Abraham J, Leffall LD. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med 2005; 11: 481–483.Google Scholar
Radke S, Pirkmaier A, Germain D. Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer. Oncogene 2005; 24: 3448–3458.Google Scholar
Rouanet P, Linares-Cruz G, Dravet F, Poujol S, Gourgou S, Simony-Lafontaine J, Grenier J, Kramar A, Girault J, Le Nestour E, Maudelonde T. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen. J Clin Oncol 2005; 23: 2980–2987.Google Scholar
Sabnis GJ, Jelovac D, Long B, Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 2005; 65: 3903–3910.Google Scholar
Sesso HD, Buring JE, Zhang SMM, Norkus EP, Gaziano JM. Dietary and plasma lycopene and the risk of breast cancer. Cancer Epidem Biom Prev 2005; 14: 1074–1081.Google Scholar
Sum EYM, Segara D, Duscio B, Bath ML, Field AS, Sutherland RL, Lindeman GJ, Visvader JE. Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. P Natl Acad Sci USA 2005; 102: 7659–7664.Google Scholar
Sun HG, Berquin IM, Edwards IJ. Omega-3 polyunsaturated fatty acids regulate syndecan-1 expression in human breast cancer cells. Cancer Res 2005; 65: 4442–4447.Google Scholar
Townsend K, Banwell CM, Guy M, Colston K, Mansi JL, Stewart PM, Campbell M, Hewison M. Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res 2005; 11: 3579–3586.Google Scholar
Vellon L, Menendez JA, Lupu R. alpha(v)beta(3) integrin regulates Heregulin (HRG)-induced cell proliferation and survival in breast cancer. Oncogene 2005; 24: 3759–3773.Google Scholar
Wu YL, Yang XJ, Ren Z, McDonnell DP, Norris JD, Willson TM, Greene GL. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell 2005; 18: 413–424.Google Scholar
Yan Y, Spieker RS, Kim M, Stoeger SM, Cowan KH. BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation. Oncogene 2005; 24: 3285–3296.Google Scholar
Yin YZ, Russell RG, Dettin LE, Bai R, Wei ZL, Kozikowski AP, Kopleovich L, Glazer RI. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res 2005; 65: 3950–3957.Google Scholar